JOURNAL OF CONTROLLED RELEASE

Scope & Guideline

Shaping the evolution of controlled release methodologies.

Introduction

Welcome to the JOURNAL OF CONTROLLED RELEASE information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of JOURNAL OF CONTROLLED RELEASE, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0168-3659
PublisherELSEVIER
Support Open AccessNo
CountryNetherlands
TypeJournal
Convergefrom 1984 to 2024
AbbreviationJ CONTROL RELEASE / J. Control. Release
Frequency24 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS

Aims and Scopes

The Journal of Controlled Release focuses on the development and application of advanced drug delivery systems and nanomedicines. Its core research areas encompass a wide array of methodologies aimed at optimizing the therapeutic efficacy and safety of drugs through controlled release mechanisms.
  1. Drug Delivery Systems:
    Research on various drug delivery systems including nanoparticles, liposomes, hydrogels, and microneedles designed to improve the bioavailability and efficacy of therapeutic agents.
  2. Nanomedicine:
    Exploration of nanotechnology applications in medicine, focusing on the design, synthesis, and evaluation of nanomaterials for targeted drug delivery and therapy.
  3. Therapeutic Formulations:
    Development of innovative formulations that enhance the delivery and release profiles of drugs, including responsive systems that react to specific biological stimuli.
  4. Biomaterials Engineering:
    Investigation of biocompatible materials for drug delivery systems, emphasizing the interaction between drugs and the biological environment to optimize therapeutic outcomes.
  5. Clinical Applications:
    Translation of laboratory findings to clinical settings, assessing the safety and efficacy of new drug delivery technologies in various therapeutic areas.
  6. Immunotherapy:
    Integration of drug delivery systems with immunotherapeutic strategies to enhance the immune response against cancer and other diseases.
The Journal of Controlled Release is witnessing exciting trends and emerging themes that reflect the evolving landscape of drug delivery research. These areas are gaining traction and are likely to shape the future of the field.
  1. Stimuli-Responsive Drug Delivery:
    Research on drug delivery systems that respond to specific stimuli (e.g., pH, temperature, or light) is increasing, enabling more precise control over drug release profiles.
  2. Extracellular Vesicles (EVs):
    The use of EVs as drug delivery vehicles is gaining prominence, leveraging their natural ability to facilitate cellular uptake and modulate immune responses.
  3. CRISPR and Gene Editing Technologies:
    The integration of CRISPR and other gene editing technologies into drug delivery systems is emerging as a powerful approach for targeted genetic therapies.
  4. Nanomaterials for Cancer Therapy:
    Innovative nanomaterials designed for cancer therapy, including those that enhance immunogenicity and target the tumor microenvironment, are rapidly advancing.
  5. Personalized Medicine Approaches:
    The shift towards personalized medicine is reflected in research aimed at tailoring drug delivery systems to individual patient needs, improving treatment outcomes.
  6. Combination Therapies:
    There is a growing trend in combining different therapeutic modalities (e.g., chemotherapy and immunotherapy) within a single delivery system to enhance therapeutic efficacy.

Declining or Waning

While the Journal of Controlled Release has maintained a strong focus on drug delivery and nanomedicine, certain areas have seen a decline in research output. These waning scopes may reflect shifting interests within the scientific community or advancements in alternative methodologies.
  1. Conventional Drug Delivery Methods:
    There is a noticeable decline in research focused on traditional drug delivery methods as the field shifts towards more innovative approaches like nanotechnology and personalized medicine.
  2. Non-targeted Drug Delivery:
    Research on non-targeted delivery systems is decreasing as there is a growing emphasis on targeted therapies that improve specificity and reduce side effects.
  3. Passive Release Mechanisms:
    Studies exploring passive release mechanisms are becoming less common, with a trend towards developing stimuli-responsive systems that offer more control over drug release.
  4. Single-Modal Therapies:
    The exploration of single-modal therapies is waning as there is a shift towards combination therapies that integrate multiple modalities for enhanced efficacy.
  5. In vitro Models:
    There is a reduction in the use of basic in vitro models for drug testing, with more research focusing on complex in vivo models that better mimic human physiology.

Similar Journals

Materials

Fostering collaboration in the evolving landscape of materials science.
Publisher: MDPIISSN: Frequency: 24 issues/year

Materials is an esteemed journal published by MDPI, dedicated to advancing the fields of Condensed Matter Physics and Materials Science. With its commitment to Open Access since its inception in 2008, the journal has made significant strides in disseminating high-quality research globally, allowing researchers, professionals, and students easy access to cutting-edge studies without financial barriers. Hailing from Switzerland, the journal has shown remarkable growth and prominence, currently ranked in the Q2 quartile in its categories according to the latest assessments, which highlights its impact within the community. As the journal converges its focus from 2008 to 2024, it aims to continually foster a robust exchange of knowledge on innovative materials and their applications, thereby supporting the evolving landscape of science and technology. With an E-ISSN of 1996-1944 and a user-friendly platform, Materials is poised to be a leading choice for scholars eager to contribute to and engage with pioneering research.

MACROMOLECULAR BIOSCIENCE

Pioneering Research at the Intersection of Biology and Materials
Publisher: WILEY-V C H VERLAG GMBHISSN: 1616-5187Frequency: 12 issues/year

MACROMOLECULAR BIOSCIENCE, published by WILEY-V C H VERLAG GMBH, is a leading journal in the fields of bioengineering, biomaterials, biotechnology, materials chemistry, and polymers and plastics. With a convergence of scientific inquiry since its inception in 2001, the journal has established itself as a vital resource for researchers and professionals exploring the interface of molecular sciences and biosystems. It boasts impressive Scopus rankings, including Q1 status in multiple categories, reflecting its significant contribution to advancing knowledge and innovation in the polymer and biomaterials domains. While the journal does not currently offer open access options, its rigorous peer-review process ensures the publication of high-quality research that fuels academic discourse. Positioned in Weinheim, Germany, MACROMOLECULAR BIOSCIENCE aims to bridge theoretical understanding with practical applications, making it an essential reference for students, academics, and industry practitioners dedicated to the evolving landscape of macromolecular bioscience.

Current Drug Delivery

Catalyzing advancements in drug delivery systems.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1567-2018Frequency: 10 issues/year

Current Drug Delivery, published by Bentham Science Publishers Ltd, serves as a vital platform for advancing the field of pharmaceutical sciences. With an ISSN of 1567-2018 and an E-ISSN of 1875-5704, this esteemed journal focuses on all aspects of drug delivery systems, encompassing innovative research and developments that aim to improve therapeutics and patient outcomes. Operating from the United Arab Emirates, it has an impressive standing reflected in its 2023 Q2 ranking in Pharmaceutical Sciences and a notable position within the 62nd percentile in Scopus’s Pharmacology, Toxicology, and Pharmaceutics category. The journal not only acts as an essential resource for researchers and professionals but it also encourages the dissemination of knowledge among students and budding scientists. With the latest articles and reviews converging from 2004 to 2024, Current Drug Delivery remains committed to offering high-quality content that enhances understanding and sparks innovation in drug delivery mechanisms.

BIOMATERIALS

Harnessing Science for Innovative Biomaterials Applications
Publisher: ELSEVIER SCI LTDISSN: 0142-9612Frequency: 36 issues/year

BIOMATERIALS, published by Elsevier Science Ltd, is a premier academic journal dedicated to the interdisciplinary field of biomaterials research. With an impressive impact factor, it ranks in the Q1 quartile across multiple categories including Bioengineering, Biomaterials, and Biophysics, showcasing its significance in advancing scientific knowledge. Established in 1980 and set to converge its discussions through 2025, this journal provides a critical platform for researchers and professionals to disseminate their findings on the development, application, and performance of biomaterials. The journal covers a wide range of topics, from the mechanics of materials to nanotechnology, and is highly regarded with top Scopus rankings in essential categories, including an exceptional position within the 99th percentile for Biophysics. Although not an open access journal, BIOMATERIALS remains vital for students and established researchers alike, ensuring accessibility to groundbreaking research in the field. Engage with cutting-edge studies that pave the way for innovative applications in medicine, engineering, and beyond.

Bioactive Materials

Catalyzing Discoveries in Bioactive Materials and Applications
Publisher: KEAI PUBLISHING LTDISSN: Frequency: 12 issues/year

Bioactive Materials, published by KEAI PUBLISHING LTD, stands as a leading Open Access journal in the fields of Biomaterials, Biomedical Engineering, and Biotechnology. Since its inception in 2016, this journal has rapidly ascended in prominence, currently holding a prestigious Q1 category ranking across multiple disciplines, reflecting its significant impact within the scientific community. With its E-ISSN 2452-199X, it spans a broad spectrum of research areas, contributing valuable insights to the ongoing discourse in bioactive materials and their applications. The journal's superior Scopus rankings further illustrate its influence, boasting impressive standings in engaging niches such as engineering and molecular biology. Bioactive Materials offers a vital platform for researchers, professionals, and students to disseminate and acquire cutting-edge knowledge, thus fostering innovation and collaboration in the rapidly evolving terrain of biomedicine. Its commitment to Open Access since 2016 enhances accessibility, ensuring that the burgeoning advancements in this field reach a global audience.

Advanced Pharmaceutical Bulletin

Fostering Excellence in Open-access Pharmaceutical Research
Publisher: TABRIZ UNIV MEDICAL SCIENCES & HEALTH SERVICESISSN: 2228-5881Frequency: 2 issues/year

Advanced Pharmaceutical Bulletin, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, serves as a pivotal platform for disseminating groundbreaking research in the field of pharmaceutical sciences. Since its inception in 2011, this open-access journal has dedicated itself to advancing knowledge in pharmacology, toxicology, and pharmaceutics, boasting an impressive Q1 ranking in miscellaneous categories and Q2 in pharmaceutical science as of 2023. The journal is noted for its rigorous peer-review process, ensuring that published work meets the highest standards of scientific inquiry. With notable rankings, including 7th out of 80 in general pharmacology and toxicology, it sits in the 91st percentile, highlighting its significance in the research community. Researchers and practitioners alike can access cutting-edge findings and innovative methodologies, promoting collaboration and knowledge within the scientific community. Based in Tabriz, Iran, the journal remains committed to fostering research excellence, making it an invaluable resource for scholars and professionals eager to contribute to the dynamic field of pharmaceuticals.

JOURNAL OF PHARMACEUTICAL SCIENCES

Exploring the frontiers of pharmacology and toxicology.
Publisher: ELSEVIER SCIENCE INCISSN: 0022-3549Frequency: 12 issues/year

The JOURNAL OF PHARMACEUTICAL SCIENCES, published by ELSEVIER SCIENCE INC, stands as a cornerstone in the field of pharmaceutical sciences, offering a platform for innovative research and advancements since its inception in 1961. With an impressive Scopus Rank of #36 out of 183 in the Pharmaceutical Science category, this journal is recognized for its commitment to disseminating high-quality, peer-reviewed studies that significantly contribute to the realms of pharmacology, toxicology, and pharmaceutics. Holding a 2023 Q2 category quartile, it attracts a diverse readership encompassing researchers, industry professionals, and students eager to advance their understanding and expertise. While the journal is not open access, it ensures valuable insights in every issue, making it an essential resource for those dedicated to the evolving landscape of pharmaceutical research. With an impact factor that reflects its relevance and influence, the JOURNAL OF PHARMACEUTICAL SCIENCES continues to shape the discourse in its domain, fostering innovation and collaboration among scholars worldwide.

Drug Delivery and Translational Research

Exploring New Frontiers in Drug Delivery and Pharmacokinetics.
Publisher: SPRINGER HEIDELBERGISSN: 2190-393XFrequency: 12 issues/year

Drug Delivery and Translational Research (ISSN: 2190-393X | E-ISSN: 2190-3948), published by Springer Heidelberg, stands at the forefront of the Pharmaceutical Sciences discipline, boasting a prestigious impact factor as evidenced by its Q1 category ranking in 2023. This esteemed journal is dedicated to the vital intersection of drug delivery systems and translational research, aiming to bridge the gap between laboratory findings and clinical applications. It features groundbreaking studies that enhance our understanding of drug pharmacokinetics, formulations, and patient-centered research, making it indispensable for researchers, professionals, and students striving to innovate and excel in the field. While the journal operates under a subscription model, its commitment to disseminating high-quality research is reflected in its Scopus rank, placing it in the top 6% of its category (Rank #11/183, 94th percentile). Since its inception in 2011, it has garnered significant attention, promoting advances in pharmacology, toxicology, and pharmaceutics, and continues to be a platform for vital discourse and discovery.

Therapeutic Delivery

Transforming Therapeutics Through Open Access Knowledge
Publisher: Newlands Press LtdISSN: 2041-5990Frequency: 12 issues/year

Therapeutic Delivery is a prestigious journal dedicated to advancing the field of Pharmaceutical Science, published by Newlands Press Ltd. Since its inception in 2010, this journal has become a vital resource for researchers and professionals alike, focusing on innovative drug delivery systems and therapeutic approaches that enhance patient care. With an impressive impact factor reflective of its credibility and scholarly influence, Therapeutic Delivery is currently ranked in the Q2 quartile and placed at Rank #64 out of 183 in the realm of Pharmacology, Toxicology, and Pharmaceutics, showcasing its prominence in the field. The journal operates with an Open Access format, ensuring that groundbreaking research is readily available to a global audience. Based in the United Kingdom, it publishes comprehensive articles that cover a wide spectrum of topics within pharmaceutical sciences, from molecular mechanisms to clinical applications, thus catering to both academic and professional readerships. Researchers, students, and industry professionals will find Therapeutic Delivery an invaluable platform for sharing insights and fostering advancements in therapeutic methodologies.

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY

Transforming Ideas into Effective Therapeutics.
Publisher: TAYLOR & FRANCIS LTDISSN: 1083-7450Frequency: 6 issues/year

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY is a premier journal published by Taylor & Francis Ltd that focuses on the latest advancements and innovations in the field of pharmaceutical science. Established in 1996, this journal has evolved to encompass a wide array of interdisciplinary studies relevant to drug development, formulation technology, and delivery systems, serving as a platform for researchers and professionals to share groundbreaking findings. With an impressive impact factor and ranked in both Q2 in Pharmaceutical Science and Q3 in Medicine (miscellaneous), it positions itself among the top-tier journals in pharmacology and toxicology. The journal's insights are critical for scholars and practitioners aiming to enhance therapeutic efficacy and safety. Access options for the content remain traditional, thus supporting a comprehensive approach to scientific literature. Throughout its converged years up to 2024, PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY continues to play a vital role in shaping pharmaceutical education and practice.